Literature DB >> 1749211

Hereditary variation of liver enzymes involved with detoxification and neurodegenerative disease.

A C Williams1, G B Steventon, S Sturman, R H Waring.   

Abstract

Enzymes involved with the metabolic transformation of xenobiotics have recently been studied in patients with the neurodegenerative diseases, Alzheimer's disease, Parkinson's disease and motor neurone disease. Defects were detected in sulphur pathways and also, in the case of Parkinson's disease, in monoamine oxidase B. The possibility exists that the ability to cope safely with endogenous and exogenous substances which have neurotoxic properties is important in the pathogenesis of these diseases. Potentially such individuals could be identified preclinically and these diseases postponed by reduction in the load of toxin or modification of the relevant enzymic activity.

Entities:  

Mesh:

Year:  1991        PMID: 1749211     DOI: 10.1007/bf01797916

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  14 in total

1.  Pesticide toxicity and motor neuron disease.

Authors:  G B Steventon; R H Waring; A C Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

2.  Monoamine oxidase B and Parkinson's disease.

Authors:  G Steventon; C Humfrey; S Sturman; R H Waring; A C Williams
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

3.  Xenobiotic metabolism in Parkinson's disease.

Authors:  G B Steventon; M T Heafield; R H Waring; A C Williams
Journal:  Neurology       Date:  1989-07       Impact factor: 9.910

4.  Production in nature of compound resembling methylphenyltetrahydropyridine, a possible cause of Parkinson's disease.

Authors:  D B Ramsden; A C Williams
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

5.  Platelet monoamine oxidase-B activity in Parkinson's disease.

Authors:  G B Steventon; S G Sturman; M T Heafield; R H Waring; J Napier; A C Williams
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1989

6.  S-methylation in motorneuron disease and Parkinson's disease.

Authors:  R H Waring; G B Steventon; S G Sturman; M T Heafield; M C Smith; A C Williams
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

7.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

Authors:  K Chiba; A Trevor; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

8.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

9.  Metabolism of low-dose paracetamol in patients with chronic neurological disease.

Authors:  G B Steventon; M T Heafield; R H Waring; A C Williams; S Sturman; M Green
Journal:  Xenobiotica       Date:  1990-01       Impact factor: 1.908

10.  Oral versus parenteral efficacy of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): differential effects on depletion of heart norepinephrine and of striatal dopamine in mice.

Authors:  R W Fuller; S K Hemrick-Luecke
Journal:  Biochem Pharmacol       Date:  1987-03-15       Impact factor: 5.858

View more
  3 in total

Review 1.  Understanding human thiol dioxygenase enzymes: structure to function, and biology to pathology.

Authors:  Bibekananda Sarkar; Mahesh Kulharia; Anil K Mantha
Journal:  Int J Exp Pathol       Date:  2017-04-24       Impact factor: 1.925

2.  Mild Cognitive Impairment, Neurodegeneration, and Personalized Lifestyle Medicine.

Authors:  Jeffrey Bland
Journal:  Integr Med (Encinitas)       Date:  2016-04

3.  Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease.

Authors:  Fiona Kerr; Oyinkan Sofola-Adesakin; Dobril K Ivanov; Jemma Gatliff; Beatriz Gomez Perez-Nievas; Hélène C Bertrand; Pedro Martinez; Rebecca Callard; Inge Snoeren; Helena M Cochemé; Jennifer Adcott; Mobina Khericha; Jorge Iván Castillo-Quan; Geoffrey Wells; Wendy Noble; Janet Thornton; Linda Partridge
Journal:  PLoS Genet       Date:  2017-03-02       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.